C
Chung-Han Lee
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 102
Citations - 4893
Chung-Han Lee is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Renal cell carcinoma & Medicine. The author has an hindex of 20, co-authored 68 publications receiving 2865 citations. Previous affiliations of Chung-Han Lee include Cornell University & University of Michigan.
Papers
More filters
Journal ArticleDOI
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.
TL;DR: The understanding of neoantigen, a non-self-antigen that arises as a result of somatic mutation, and new developments in the quest to use them in cancer immunotherapy are discussed.
Journal ArticleDOI
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma.
Maria I. Carlo,Semanti Mukherjee,Semanti Mukherjee,Diana Mandelker,Joseph Vijai,Joseph Vijai,Yelena Kemel,Liying Zhang,Andrea Knezevic,Sujata Patil,Ozge Ceyhan-Birsoy,Kuo-Cheng Huang,Almedina Redzematovic,Devyn Taylor Coskey,Carolyn Stewart,Nisha Pradhan,Angela G. Arnold,A. Ari Hakimi,Ying-Bei Chen,Jonathan A. Coleman,David M. Hyman,Marc Ladanyi,Karen Cadoo,Michael Walsh,Zsofia K. Stadler,Chung-Han Lee,Darren R. Feldman,Martin H. Voss,Mark E. Robson,Robert J. Motzer,Kenneth Offit,Kenneth Offit +31 more
TL;DR: Current referral criteria for genetic testing did not identify a substantial portion of patients with mutations, supporting the role of a more inclusive sequencing approach.
Journal ArticleDOI
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Chung-Han Lee,Amishi Yogesh Shah,Drew W. Rasco,Arpit Rao,Matthew H. Taylor,Christopher Di Simone,James J. Hsieh,Alvaro Pinto,David R. Shaffer,Regina Gironés Sarrió,Allen Lee Cohn,Nicholas J. Vogelzang,Mehmet Asim Bilen,Sara Gunnestad Ribe,Musaberk Goksel,Øyvind Krohn Tennøe,Donald A. Richards,Randy F. Sweis,Jay Courtright,Daniel Heinrich,Sharad Jain,Jane Wu,Emmett V. Schmidt,Rodolfo F. Perini,Peter Kubiak,Chinyere E. Okpara,Alan D. Smith,Robert J. Motzer +27 more
TL;DR: Eisai et al. as discussed by the authors evaluated the combination of lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma (RCC) and showed encouraging antitumour activity and manageable safety profile.
Journal ArticleDOI
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I. Carlo,Ana M. Molina,Yulia Lakhman,Sujata Patil,Kaitlin M. Woo,John DeLuca,Chung-Han Lee,James J. Hsieh,Darren R. Feldman,Robert J. Motzer,Martin H. Voss +10 more
TL;DR: BEZ235 twice daily resulted in significant toxicity without objective responses; further development of this compound will not be pursued in this disease.
Journal ArticleDOI
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
Jianing Xu,Can G. Pham,Steven K. Albanese,Yiyu Dong,Toshinao Oyama,Chung-Han Lee,Vanessa Rodrik-Outmezguine,Zhan Yao,Song Han,David J. Chen,Daniel L. Parton,John D. Chodera,Neal Rosen,Emily H. Cheng,James J. Hsieh +14 more
TL;DR: In this paper, the authors identified three distinct mechanisms of hyperactivation, including reduced binding to DEP domain-containing MTOR-interacting protein (DEPTOR), resistance to regulatory associated protein of mTOR-mediated (RAPTOR)-mediated) suppression, and altered kinase kinetics.